Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation

Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at other companies

Ready Capital logo
Ready CapitalRC
-$8.33M-114%
Tapestry, Inc. logo
Tapestry, Inc.TPR
-$1.25B-193%
Ryder System logo
Ryder SystemR
$9M+229%
American Homes 4 Rent logo
American Homes 4 RentAMH
$166.33M-56.5%
The Kraft Heinz Company logo
The Kraft Heinz CompanyKHC
-$908M-52.3%
Globalstar logo
GlobalstarGSAT
$3.75M-69.5%

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
BioMarin Pharmaceuticals (BMRN) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of $1.76B in Q1 2026.
How has BioMarin Pharmaceuticals's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
BioMarin Pharmaceuticals's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation increased by 1561.7% year-over-year, from $105.96M to $1.76B.